Developing Symptom Lists for People with Cancer Treated with Targeted Therapies.
Journal
Targeted oncology
ISSN: 1776-260X
Titre abrégé: Target Oncol
Pays: France
ID NLM: 101270595
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
pubmed:
10
11
2020
medline:
15
10
2021
entrez:
9
11
2020
Statut:
ppublish
Résumé
Targeted therapies (TTs) have revolutionised cancer treatment with their enhanced specificity of action. Compared with conventional therapies, TTs are delivered over a longer period and often have unusual symptom profiles. Patient-reported outcome measures such as symptom side-effect lists need to be developed in a time-efficient manner to enable a rapid and full evaluation of new treatments and effective clinical management OBJECTIVE: The aim of this study was to develop a set of TT-related symptoms and identify the optimal method for developing symptom lists. Symptoms from TT treatment in the context of Chronic Myeloid Leukaemia (CML), HER2-positive breast cancer, or Gastrointestinal Stromal Tumours (GIST) were identified through literature reviews, interviews with healthcare professionals (HCPs) and patients, and patient focus groups. The symptom set was then pilot tested in patients across the three cancer diagnoses: The number of items derived from each source (literature, patients, or HCPs) were compared. A total of 316 patients and 86 HCPs from 16 countries participated. An initial set of 209 symptoms was reduced to 61 covering 12 symptom categories. Patient interviews made the greatest contribution to the item set. Symptom lists should be created based on input from patients. The item set described will be applicable to the assessment of new TTs, and in monitoring treatment.
Sections du résumé
BACKGROUND
Targeted therapies (TTs) have revolutionised cancer treatment with their enhanced specificity of action. Compared with conventional therapies, TTs are delivered over a longer period and often have unusual symptom profiles. Patient-reported outcome measures such as symptom side-effect lists need to be developed in a time-efficient manner to enable a rapid and full evaluation of new treatments and effective clinical management OBJECTIVE: The aim of this study was to develop a set of TT-related symptoms and identify the optimal method for developing symptom lists.
PATIENTS AND METHODS
Symptoms from TT treatment in the context of Chronic Myeloid Leukaemia (CML), HER2-positive breast cancer, or Gastrointestinal Stromal Tumours (GIST) were identified through literature reviews, interviews with healthcare professionals (HCPs) and patients, and patient focus groups. The symptom set was then pilot tested in patients across the three cancer diagnoses: The number of items derived from each source (literature, patients, or HCPs) were compared.
RESULTS
A total of 316 patients and 86 HCPs from 16 countries participated. An initial set of 209 symptoms was reduced to 61 covering 12 symptom categories. Patient interviews made the greatest contribution to the item set.
CONCLUSIONS
Symptom lists should be created based on input from patients. The item set described will be applicable to the assessment of new TTs, and in monitoring treatment.
Identifiants
pubmed: 33165751
doi: 10.1007/s11523-020-00769-z
pii: 10.1007/s11523-020-00769-z
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
95-107Références
US Food and Drug Administration. Guidance for industry: patient-reported outcome measures—use in medical product development to support labeling claims
Basch E. Patient-reported outcomes—harnessing patients’ voices to improve clinical care. N Engl J Med. 2017;376(2):105–8.
doi: 10.1056/NEJMp1611252
Kluetz PG, Slagle A, Papadopoulos EJ, Johnson LL, Donoghue M, Kwitkowski VE, et al. Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms. Clin Cancer Res. 2016;22(7):1553–8.
doi: 10.1158/1078-0432.CCR-15-2035
European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man. The use of patient-reported outcome (PRO) measures in oncology studies. Canary Wharf, London. EMA; 2016. https://www.ema.europa.eu/en/appendix-2-guideline-evaluation-anticancer-medicinal-products-man-use-patient-reported-outcome-pro
Groenvold M, Aaronson NK, Darlington ASE, Fitzsimmons D, Greimel E, Holzner B, et al. Focusing on core patient-reported outcomes in cancer clinical trials—letter. Clin Cancer Res. 2016;22(22):5617.
doi: 10.1158/1078-0432.CCR-16-1529
Bottomley A, Reijneveld JC, Koller M, Flechtner H, Tomaszewski KA, Greimel E, et al. Current state of quality of life and patient-reported outcomes research. Eur J Cancer. 2019;121:55–63.
doi: 10.1016/j.ejca.2019.08.016
Judson TJ, Bennett AV, Rogak LJ, Sit L, Barz A, Kris MG, et al. Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy. J Clin Oncol. 2013;31(20):2580–5.
doi: 10.1200/JCO.2012.47.6804
Warrington L, Absolom K, Holch P, Gibson A, Clayton B, Velikova G. Online tool for monitoring adverse events in patients with cancer during treatment (eRAPID): field testing in a clinical setting. BMJ Open. 2019;9(1):e025185.
doi: 10.1136/bmjopen-2018-025185
Snyder CF, Blackford AL, Wolff AC, Carducci MA, Herman JM, Wu AW, et al. Feasibility and value of Patient Viewpoint: a web system for patient-reported outcomes assessment in clinical practice. Psychooncology. 2013;22(4):895–901.
doi: 10.1002/pon.3087
Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol. 2016;34(6):557–65.
doi: 10.1200/JCO.2015.63.0830
National Cancer Institute. Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™). https://outcomes.cancer.gov/tools/pro-ctcae.html .
Petersen MA, Aaronson NK, Arraras JI, Chie W-C, Conroy T, Costantini A, et al. The EORTC CAT core—the computer adaptive version of the EORTC QLQ-C30 questionnaire. Eur J Cancer. 2018;100:8–16.
doi: 10.1016/j.ejca.2018.04.016
Cella DGR, Lai JS, Choi S. The future of outcomes measurement: item banking, tailored short-forms, and computerized adaptive assessment. Qual Life Res. 2007;16(Suppl 1):133–41.
doi: 10.1007/s11136-007-9204-6
de Wit M, Hajos T. Health-related quality of life. In: Gellman MD, Turner JR, editors. Encyclopedia of behavioral medicine. New York: Springer; 2013. p. 929–31.
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001;61(Suppl 2):37–42.
doi: 10.1159/000055400
Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344(14):1038–42.
doi: 10.1056/NEJM200104053441402
Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344(14):1052–6.
doi: 10.1056/NEJM200104053441404
Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472–80.
doi: 10.1056/NEJMoa020461
Sodergren SC, White A, Efficace F, Sprangers M, Fitzsimmons D, Bottomley A, et al. Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group. Critic Rev Oncol Hematol. 2014;91(1):35–46.
doi: 10.1016/j.critrevonc.2014.01.002
Guérin A, Chen L, Ionescu-Ittu R, Marynchenko M, Nitulescu R, Hiscock R, et al. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Curr Med Res Opin. 2014;30(11):2317–28.
doi: 10.1185/03007995.2014.944973
Efficace F, Rosti G, Aaronson N, Cottone F, Angelucci E, Molica S, et al. Patient- versus physician reporting of symptoms and health status in chronic myeloid leukemia. Haematologica. 2014;99(4):788–93.
doi: 10.3324/haematol.2013.093724
Johnson CD, Aaronson N, Blazeby J et al. EORTC Quality of Life Group: guidelines for developing questionnaire modules. Brussels: EORTC Quality of Life Group; 2011.
Kuliś D BA, Whittaker C, van de Poll-Franse LV, Darlington A, Holzner B, Koller M, Reijneveld JC, Tomaszewski K, Grønvold M, on behalf of the EORTC Quality of Life Group, editor The Use of the EORTC Item Library to Supplement EORTC Quality of Life Instruments. ISPOR 20th Annual European Congress. Glasgow: Value in Health. 2017.
Vachalec SBK, Bottomley A, Blazeby J, Flechtner H, Ruyskart P. EORTC item bank guidelines. Brussels: EORTC Publications; 2001.
Mouillet G, Fritzsch J, Paget-Bailly S, Pozet A, Es-Saad I, Meurisse A, et al. Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol. Health Quality Life Outcomes. 2019;17(1):25.
doi: 10.1186/s12955-019-1085-1
Bell JA, Galaznik A, Pompilus F, Strzok S, Bejar R, Scipione F, et al. A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Patient Rep Outcomes. 2019;3(1):35.
doi: 10.1186/s41687-019-0123-4
Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851–7.
doi: 10.1200/JCO.2015.66.2866
Efficace F, Baccarani M, Breccia M, Saussele S, Abel G, Caocci G, et al. International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res. 2014;23(3):825–36.
doi: 10.1007/s11136-013-0523-5
Milanezi FCS, Schmitt FC. EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. Expert Rev Mol Diagn. 2008;8:417–34.
doi: 10.1586/14737159.8.4.417
Baar J. Biological therapy of breast cancer: recent clinical applications. Curr Opin Investig Drugs. 2007;8:987–95.
pubmed: 18058569
Verweij JCP, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364(9440):1127–34.
doi: 10.1016/S0140-6736(04)17098-0
Springfield (MA). Merriam-Webster I. Webster's third new international dictionary of the English language, unabridged. 2002.
Sodergren SC, Copson E, White A, Efficace F, Sprangers M, Fitzsimmons D, et al. Systematic review of the side effects associated with anti-HER2-targeted therapies used in the treatment of breast cancer, on behalf of the EORTC quality of life group. Target Oncol. 2016;11(3):277–92.
doi: 10.1007/s11523-015-0409-2
Efficace F, Cocks K, Breccia M, Sprangers M, Meyers CA, Vignetti M, et al. Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes. Crit Rev Oncol Hematol. 2012;81(2):123–35.
doi: 10.1016/j.critrevonc.2011.02.007
Bjelic-Radisic V, Cardoso F, Cameron D, Brain E, Kuljanic K, da Costa RA, et al. An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45. Ann Oncol. 2020;31(2):283–8.
doi: 10.1016/j.annonc.2019.10.027
Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol. 2004;22(4):714–24.
doi: 10.1200/JCO.2004.06.078
Kluetz PG, Chingos DT, Basch EM, Mitchell SA. Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the national cancer institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Am Soc Clin Oncol Educ Book. 2016;36:67–73.
doi: 10.14694/EDBK_159514